탭메뉴
| 번호 | 구분 | 제목 |
|---|---|---|
| 161 | (국외)SCI | Response to Letter Regarding Article, Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study |
| 160 | (국외)SCI | Association of non-alcoholic fatty liver disease withcardiovascular disease and all cause death in patients with type 2diabetes mellitus: nationwide population based study |
| 159 | (국외)SCI | Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study |
| 158 | (국외)SCI | A cohort study found a high risk of end-stage kidney disease associated with acromegaly |
| 157 | (국외)SCI | Different Molecular Phenotypes of Progression in BRAFandRAS-Like Papillary Thyroid Carcinoma |
| 156 | (국외)SCI | Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma |
| 155 | (국외)기타 | Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study |
| 154 | (국외)SCI | Efficacy and safety of monotherapy with enavogliflozinin Korean patients with type 2 diabetes mellitus: Resultsof a 12-week, multicentre, randomized, double-blind,placebo-controlled, phase 2 trial |
| 153 | (국외)SCI | Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial |
| 152 | (국외)SCI | Efficacy and safety of enavogliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: a double-blind, randomised study with dapagliflozin as a comparator: ENHANCE-D study |
1
Copyright ⓒ chamc, All rights reserved.
